XML 15 R3.htm IDEA: XBRL DOCUMENT v3.25.2
Consolidated Income Statements - EUR (€)
€ in Millions
 6 Months Ended
Jun. 30, 2025
Jun. 30, 2024
Profit (loss) [abstract]    
Net sales € 19,889 € 18,360 [1],[2]
Other revenues 1,452 1,529 [2],[3]
Cost of sales (5,881) (5,966) [2]
Gross profit 15,460 13,923 [2]
Research and development expenses (3,717) (3,335) [2]
Selling and general expenses (4,506) (4,303) [2]
Other operating income 533 563 [2]
Other operating expenses (2,476) (1,977) [2]
Amortization of intangible assets (777) (898) [2]
Impairment of intangible assets (210) 371 [2]
Fair value remeasurement of contingent consideration (61) (66) [2]
Restructuring costs and similar items [4] (430) (1,060) [2]
Other gains and losses, and litigation (57) (450) [2]
Operating income 3,759 2,768 [5]
Financial expenses (361) (583) [5],[6]
Financial income 184 277 [5],[6]
Income before tax and investments accounted for using the equity method 3,582 2,462 [2],[7]
Income tax expense (711) (379) [2],[7]
Share of profit/(loss) from investments accounted for using the equity method 85 (22) [2]
Net income from continuing operations 2,956 2,061 [2]
Net (income)/loss of the exchanged/held-for-exchange Animal Health business 2,881 202 [2]
Net income 5,837 2,263 [8]
Net income attributable to non-controlling interests 25 17 [2]
Net income attributable to equity holders of Sanofi € 5,812 € 2,246 [2]
Average number of shares outstanding (in shares) 1,225,500,000 1,249,400,000 [2]
Average number of shares after dilution (in shares) 1,230,700,000 1,253,800,000 [2]
Basic earnings per share (in euros per share) € 4.74 € 1.80 [2]
Diluted earnings per share (in euros per share) 4.72 1.79 [2]
Basic earnings per share excluding the exchanged/held-for-exchangeAnimal Health business (in euros per share) 2.40 1.64 [2]
Basic earnings (loss) per share from discontinued operations 2.34 0.16 [2]
Diluted earnings (loss) per share from discontinued operations 2.33 0.16 [2]
Diluted earnings per share excluding the exchanged/held-for-exchangeAnimal Health business (in euros per share) € 2.39 € 1.63 [2]
[1] Figures for 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.
[2] Figures for the 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.
[3]
(a)    Figures for the 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.
[4]
(a) Figures for 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.
[5] Figures for the 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.
[6] Figures for 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.
[7]
(a) Figures for the 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.
[8] Figures for the 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.